Tableting of specific polymer stabilizers

A method for manufacturing a tablet, which comprises the steps of:

• (A) filling a starting material, which is in a solid form and does not contain a solvent, in a first open cavity, which is formed by a first punch and a die, to obtain a second open cavity, which is filled at least partly with the starting material,
• wherein solid form of the starting material excludes that the starting material is a liquid or a gas,
• (B) closing the second open cavity by a second punch to obtain a first closed cavity,
• (C) compressing the starting material at a compression temperature below 37° C. by moving at least one out of the first punch and the second punch to obtain a second closed cavity, which has a smaller volume than the first closed cavity, which results in formation of a trapped tablet of the starting material in the second closed cavity,
• (D) removing the trapped tablet to obtain the tablet, which has a tablet temperature below 37° C. directly after removal,
• wherein the steps (A), (B), (C) and (D) are conducted in a tablet press,
• wherein the starting material is solid at 37° C. and 101.32 KPa and comprises
• (i) 60 to 100 wt. % of a first polymer stabilizer, which is
• (i-1) tris(2,4-ditert-butylphenyl) phosphite (CAS-No. 31570-04-4),
• (i-2) bis(2,4-dicumylphenyl) pentaerythritol diphosphite (CAS-No. 154862-43-8),
• (i-3) bis(2,4-ditert-butylphenyl)pentaerythritol diphosphite (CAS-No. 26741-53-7),
• (i-4) tetrakis-[3-(3,5-ditert-butyl-4-hydroxy-phenyl)-propionyloxymethyl]methane (CAS-No. 6683-19-8),
• (i-5) 3-(3,5-ditert-butyl-4-hydroxy-phenyl)-propionic acid stearyl ester (CAS-No. 2082-79-3),
• (i-6) 3-(3,5-ditert-butyl-4-hydroxy-phenyl)-N-[6-[3-(3,5-ditert-butyl-4-hydroxy-phenyl)propanoylamino]hexyl]propanamide (CAS-No. 23128-74-7),
• (i-7) 3-(3,5-ditert-butyl-4-hydroxyphenyl)-N′-[3-(3,5-ditert-butyl-4-hydroxyphenyl)propanoyl]propanehydrazide (CAS-No. 3268-78-8),
• (i-8) 2-[2-[2-[3-(3-tert-butyl-4-hydroxy-5-methyl-phenyl)propanoyloxy]-ethoxy]ethoxy]ethyl 3-(3-tert-butyl-4-hydroxy-5-methyl-phenyl)propanoate (CAS-No. 36443-68-2),
• (i-9) 4-[[3,5-bis[(3,5-ditert-butyl-4-hydroxy-phenyl)methyl]-2,4,6-trimethyl-phenyl]methyl]-2,6-ditert-butyl-phenol (CAS-No. 1709-70-2),
• (i-10) 1,3,5-tris(3,5-ditert-butyl-4-hydroxybenzyl)-1,3,5-triazine-2,4,6-(1H,3H,5H)-trione (CAS-No. 27676-62-6),
• (i-11) bis[3,3-bis(4′-hydroxy-3′-tert-butylphenyl) butanoic acid] glycol ester (CAS-No. 32509-66-3),
• (i-12) N,N-dioctadecylhydroxylamine (CAS-No. 123250-74-8),
• (i-13) dodecyl 3-(3-dodecoxy-3-oxo-propyl) sulfanylpropanoate (CAS-No. 123-28-4),
• (i-14) octadecyl 3-(3-octadecoxy-3-oxo-propyl) sulfanylpropanoate (CAS-No. 693-36-7),
• (i-15) pentaerythritol tetrakis[3-dodecylthio proprionate] (CAS-No. 29598-76-3),
• (i-16) bis(2,2,6,6-tetramethyl-4-piperidyl) decanedioate (CAS-No. 52829-07-9),
• (i-17) (2-hydroxy-4-octoxy-phenyl)-phenyl-methanone (CAS-No. 1843-05-6),
• (i-18) 2-tert-butyl-6-(5-chlorobenzotriazol-2-yl)-4-methyl-phenol (CAS-No. 3896-11-5),
• (i-19) 2-(4,6-diphenyl-1,3,5-triazin-2-yl)-5-hexoxy-phenol (CAS-No. 147315-50-2),
• (i-20) 2-[4,6-bis(4-phenylphenyl)-1,3,5-triazin-2-yl]-5-(2-ethylhexoxy)phenol (CAS-No. 204583-39-1),
• (i-21) 2-[4,6-bis(2,4-dimethylphenyl)-1,3,5-triazin-2-yl]-5-[3-(2-ethylhexoxy)-2-hydroxy-propoxy]phenol (CAS-No. 137658-79-8),
• (i-22) butanedioic acid, 1,4-dimethyl ester, polymer with 4-hydroxy-2,2,6,6-tetramethyl-1-piperidineethanol (CAS-No. 65447-77-0),
• (i-23) N,N′,N″,N′″-tetrakis-(2,4-bis[N-(1-cyclohexyloxy-2,2,6,6-tetramethylpiperidin-4-yl)-butylamino]-1,3,5-triazin-6-yl)-1,5,8,12-tetrazadodecane (CAS-No. 122587-07-9),
• (i-24) N,N′,N″,N″″-Tetrakis-(2,4-bis[N-(1-cyclohexyloxy-2,2,6,6-tetramethylpiperidin-4-yl)-butylamino]-1,3,5-triazin-6-yl)-1,5,8,12-tetrazadodecane (CAS-No. 106990-43-6),
• (i-25) N,N′-bis-(2,4-bis[N-(1-propoxy-2,2,6,6-tetramethylpiperidin-4-yl)-butylamino]-1,3,5-triazin)-N,N′-bis[N-(1-propoxy-2,2,6,6-tetramethylpiperidin-4-yl)]-1,8-diazaoctane (CAS-No. 1271737-36-0),
• (i-26) poly[[6-[butyl(2,2,6,6-tetramethyl-4-piperidinyl)amino]-1,3,5-triazine-2,4-diyl][(2,2,6,6-tetramethyl-4-piperidinyl)imino]-1,6-hexanediyl[(2,2,6,6-tetramethyl-4-piperidinyl)imino]], α-[[6-[[4,6-bis(dibutylamino)-1,3,5-triazin-2-yl](2,2,6,6-tetramethyl-4-piperidinyl)amino]hexyl](2,2,6,6-tetramethyl-4-piperidinyl)amino]-ω-[4,6-bis(dibutylamino)-1,3,5-triazin-2-yl]-(CAS-No. 195300-91-5),
• (i-27) poly[6-[butyl(2,2,6,6-tetramethyl-1-propoxy-4-piperidinyl)amino]-1,3,5-triazine-2,4-diyl][(2,2,6,6-tetramethyl-1-propoxy-4-piperidinyl)imino]-1,6-hexanediyl[(2,2,6,6-tetramethyl-1-propoxy-4-piperidinyl)imino]], α-[[6-[[4,6-bis(dibutylamino)-1,3,5-triazin-2-yl](2,2,6,6-tetramethyl-1-propoxy-4-piperidinyl)amino]hexyl](2,2,6,6-tetramethyl-1-propoxy-4-piperidinyl)amino]-ω[4,6-bis(dibutylamino)-1,3,5-triazin-2-yl]-(CAS-No. 297748-93-7),
• (i-28) poly[[6 [(1,1,3,3-tetramethylbutyl)amino]-1,3,5-triazine-2,4-diyl][(2,2,6,6-tetramethyl-4-piperidinyl)imino]-1,6-hexanediyl[(2,2,6,6-tetramethyl-4-piperidinyl)imino]] (CAS-No. 71878-19-8),
• (i-29) tetrakis(1,2,2,6,6-pentamethyl-4-piperidyl) butane-1,2,3,4-tetracarboxylate (CAS-No. 91788-83-9), or a mixture thereof,
• (ii) 0 to 40 wt. % of a second polymer stabilizer, which is zinc stearate, calcium stearate, magnesium stearate or a mixture thereof,
• (iii) 0 to 34 wt. % of a third polymer stabilizer, which is zinc oxide, hydrotalcite, sodium benzoate or a mixture thereof,
• (iv) 0 to 20 wt. % of a further ingredient, which is different to the first polymer stabilizer, the second polymer stabilizer and the third polymer stabilizer,
• wherein the sum of components (i), (ii), (iii) and (iv) is 100 wt. %, wherein the tablet has a weight above 20 mg and below 330 mg and a cross-section dimension above 3 mm and below 18 mm.